SAN ANTONIO (EGMN) - Measurement of pretreatment serum tissue inhibitor of metalloproteinase-1 in combination with human epidermal growth factor receptor 2 testing provides added prognostic value over HER2 alone in metastatic breast cancer patients, study data suggest.The study, presented at the San Antonio Breast Cancer Symposium, was conducted in conjunction with a phase III double-blind trial of first-line hormonal therapy with letrozole versus tamoxifen in 522 postmenopausal women with advanced...